Q2 2011 · —
Revenue$64.57M$64.57M ±0.0% vs Q2 2010+26.9% vs Q1 2011
Net Income$33.20M$33.20M ±0.0% vs Q2 2010+52.1% vs Q1 2011
EPS Diluted$0.71$0.71 ±0.0% vs Q2 2010+47.9% vs Q1 2011
Gross Profit$60,094,000±0.0%
Operating Income$33,859,000+220.0%
Operating Cash Flowderived$37,436,000—
Free Cash Flowderived$37,341,000—
Margins · derived
Gross margin93.1%±0.0 pt vs Q2 2010
Operating margin52.4%+36.1 pt vs Q2 2010
Net margin51.4%±0.0 pt vs Q2 2010
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2011 | Q2 2010 |
|---|---|---|
| Revenue | $64.57M | $64.57M |
| Net Income | $33.20M | $33.20M |
| EPS Diluted | $0.71 | $0.71 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR